Volume 34, Issue 11 pp. 1999-2003
Hepatology

Improvement of hyponatremia in cirrhosis is associated with improved complex information processing

Hugh Watson

Corresponding Author

Hugh Watson

Infectious Diseases Research, Sanofi-Aventis R&D, Marcy l'Etoile, France

Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark

Correspondence

Dr Hugh Watson, Evotec-ID, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy l'Etoile, France.

Email: [email protected]

Search for more papers by this author
Monica Guevara

Monica Guevara

Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigaciones en Red Hepatologia y Digestivas (CIBEReHD), Barcelona, Spain

Search for more papers by this author
Hendrik Vilstrup

Hendrik Vilstrup

Department of Gastroenterology and Hepatology, Aarhus University Hospital, Aarhus, Denmark

Search for more papers by this author
Pere Ginès

Pere Ginès

Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigaciones en Red Hepatologia y Digestivas (CIBEReHD), Barcelona, Spain

Search for more papers by this author
First published: 09 April 2019
Citations: 10
Declaration of conflict of interest: Hugh Watson was formerly an employee of Sanofi-Aventis R&D and holds stocks in Sanofi. Pere Gines has consulted for Sanofi-Aventis R&D. Monica Guevara and Hendrik Vilstrup have no conflicts of interest to declare.

Abstract

Background and Aim

Hyponatremia, a cause of brain dysfunction and risk factor for hepatic encephalopathy, is frequent in patients with advanced cirrhosis and ascites. The interdependence of liver failure and hyponatremia makes it difficult to separate the effects of each on cognitive function. The objective was to assess whether an increase in plasma sodium in patients with cirrhosis and ascites leads to an improvement in cognitive function.

Methods

This is a post-hoc analysis of 250 cirrhosis patients without overt hepatic encephalopathy randomized to receive either placebo or satavaptan, a vasopressin V2 antagonist. The exposure was plasma sodium, and the outcome was the trail-making test (TMT) parts A and B, which assesses speed of information processing, performed before the study starts and after 14 days. The results were analyzed by initial and change to final sodium concentration.

Results

At entry, the patients with normonatremia exhibited better results on both the TMT-A (median 56 vs 77.5 s for patients with sodium ≤ 130 mmol/L [P = 0.0059]) and the TMT-B (median 127 vs 170 s for patients with sodium ≤ 130 mmol/L [P = 0.0066]), unrelated to age. Improvement of hyponatremia was more common in patients who received satavaptan (59.7%) than placebo (18.5%). Correction of hyponatremia did not shorten the simple TMT-A but markedly improved the complex TMT-B by an average of 20 s compared with 6.5 s in those with continuing hyponatremia (P = 0.02). Liver status measures remained stable during the period reported.

Conclusions

These data suggest that improvement of hyponatremia in patients with cirrhosis leads to an increase in the speed of complex information processing.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.